Literature DB >> 28453967

Therapeutic vaccination for chronic hepatitis B.

Anna D Kosinska1, Tanja Bauer1, Ulrike Protzer2.   

Abstract

A therapeutic vaccine is meant to activate the patient's immune system to fight and finally control or ideally eliminate an already established infectious pathogen. Whereas the success of prophylactic vaccination is based on rapid antibody-mediated neutralization of an invading pathogen, control and elimination of persistent viruses such as hepatitis, herpes or papilloma viruses requires multi-specific and polyfunctional effector T cell responses. These are ideally directed against continuously expressed viral antigens to keep the pathogen in check. Activation of a humoral immune response in order to lower viral antigen load and to limit virus spread, however, confers an additional benefit. Therapeutic vaccines are under development for a number of chronic infections and require an intelligent vaccine design. Hepatitis B virus (HBV) infection may serve as a prime example since a spontaneous, immune-mediated recovery of chronic hepatitis B and an elimination of the virus is possible even if it is observed only in very rare cases. In this review, we summarize the current knowledge and potential improvements of therapeutic vaccines for chronic hepatitis B.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28453967     DOI: 10.1016/j.coviro.2017.03.011

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  19 in total

1.  Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8+ T cell responses in naïve and persistently infected mice and protects from challenge.

Authors:  Carolina Chiale; Safiehkhatoon Moshkani; John K Rose; Michael D Robek
Journal:  Antiviral Res       Date:  2019-05-30       Impact factor: 5.970

Review 2.  HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications.

Authors:  Carolina Boni; Valeria Barili; Greta Acerbi; Marzia Rossi; Andrea Vecchi; Diletta Laccabue; Amalia Penna; Gabriele Missale; Carlo Ferrari; Paola Fisicaro
Journal:  Int J Mol Sci       Date:  2019-06-05       Impact factor: 5.923

3.  A dendritic cell receptor-targeted chimeric immunotherapeutic protein (C-HBV) for the treatment of chronic hepatitis B.

Authors:  Allan Ma; Bruce Motyka; Klaus Gutfreund; Yuenian Eric Shi; Rajan George
Journal:  Hum Vaccin Immunother       Date:  2019-12-12       Impact factor: 3.452

4.  Patients' high acceptability of a future therapeutic HIV vaccine in France: a French paradox?

Authors:  Svetlane Dimi; David Zucman; Olivier Chassany; Christophe Lalanne; Thierry Prazuck; Emmanuel Mortier; Catherine Majerholc; Isabelle Aubin-Auger; Pierre Verger; Martin Duracinsky
Journal:  BMC Infect Dis       Date:  2019-05-09       Impact factor: 3.090

5.  Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection.

Authors:  Anna D Kosinska; Abdul Moeed; Nina Kallin; Julia Festag; Jinpeng Su; Katja Steiger; Marie-Louise Michel; Ulrike Protzer; Percy A Knolle
Journal:  Sci Rep       Date:  2019-07-25       Impact factor: 4.379

6.  Virus-like Vesicles Expressing Multiple Antigens for Immunotherapy of Chronic Hepatitis B.

Authors:  Timur O Yarovinsky; Stephen W Mason; Manisha Menon; Marie M Krady; Maria Haslip; Bhaskara R Madina; Xianyong Ma; Safiehkhatoon Moshkani; Carolina Chiale; Anasuya Chattopadhyay Pal; Bijan Almassian; John K Rose; Michael D Robek; Valerian Nakaar
Journal:  iScience       Date:  2019-10-24

7.  Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22-23 March 2017.

Authors:  M Teresa Aguado; Jane Barratt; John R Beard; Bonnie B Blomberg; Wilbur H Chen; Julian Hickling; Terri B Hyde; Mark Jit; Rebecca Jones; Gregory A Poland; Martin Friede; Justin R Ortiz
Journal:  Vaccine       Date:  2018-01-12       Impact factor: 3.641

8.  In Silico Prediction of Human Leukocytes Antigen (HLA) Class II Binding Hepatitis B Virus (HBV) Peptides in Botswana.

Authors:  Wonderful Tatenda Choga; Motswedi Anderson; Edward Zumbika; Bonolo B Phinius; Tshepiso Mbangiwa; Lynnette N Bhebhe; Kabo Baruti; Peter Opiyo Kimathi; Kaelo K Seatla; Rosemary M Musonda; Trevor Graham Bell; Sikhulile Moyo; Jason T Blackard; Simani Gaseitsiwe
Journal:  Viruses       Date:  2020-07-06       Impact factor: 5.818

Review 9.  Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection.

Authors:  Ruben C Hoogeveen; André Boonstra
Journal:  Front Immunol       Date:  2020-03-04       Impact factor: 7.561

10.  A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice.

Authors:  Robbert Boudewijns; Ji Ma; Johan Neyts; Kai Dallmeier
Journal:  JHEP Rep       Date:  2021-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.